Pharmaceutical

Sarepta’s Elevidys secures US label expansion for DMD

Sarepta’s stock rose by over 36% following the positive news of the FDA expanding the gene therapy’s US label.

Jun 22, 2024 - 04:00
Sarepta’s Elevidys secures US label expansion for DMD
Sarepta’s stock rose by over 36% following the positive news of the FDA expanding the gene therapy’s US label.
Read the original article

Tags:

Previous Article

EHA 2024: Monoclonal antibodies continue to dominate multiple myeloma treatments

Next Article

Tectonic bets on GPCR heart failure drug following reverse merger with Avrobio

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Weight loss drug Wegovy improves function in people with common type of heart failure

STAT+: Weight loss drug Wegovy improves function in peo...

Aug 25, 2023

Key House Democrat demands NIH answer for pace of long Covid research

Key House Democrat demands NIH answer for pace of long ...

May 11, 2023

STAT+: Bristol Myers to purchase Karuna, maker of schizophrenia drug, for $14 billion

STAT+: Bristol Myers to purchase Karuna, maker of schiz...

Dec 23, 2023